News Center

News Center

Shengshi Taikе partners with Yunxuan Pharmaceutical to broadly deploy CXCR4 antagonists.

Release date:

2020-04-16

Recently, Shengshi Taikang, which focuses on both internal R&D and strategic external collaborations, announced that it has signed an exclusive cooperation and licensing agreement with Yunxuan Pharmaceutical, securing global exclusive rights for the development and commercialization of a preclinical-stage CXCR4 antagonist—a promising candidate targeting chemokine receptor type 4.

CXCR4 belongs to the chemokine receptor family and forms the CXCR4/SDF-1 signaling axis when interacting with its natural ligand, stromal cell-derived factor-1 (SDF-1). This axis plays critical roles in malignant tumor invasion and metastasis, stem cell migration and homing, immune and inflammatory responses in the body, and HIV infection. According to cutting-edge international research, this selective antagonist can be applied in the following therapeutic areas: ① Overcoming brain metastases from malignant tumors, enhancing combination immunotherapy to tackle primary and secondary drug resistance in cancers, synergizing with anti-angiogenic agents to prevent tumor stem cells from escaping treatment, and pairing with radiotherapy and chemotherapy to reduce tumor recurrence. ② Serving as a small-molecule stem cell mobilizer, it can be used in first-line consolidation and second-line salvage autologous hematopoietic stem cell transplantation for patients with multiple myeloma and non-Hodgkin lymphoma. ③ Treating WHIM syndrome, a rare hereditary primary autoimmune disorder that currently lacks approved effective therapies.

Professor Zhang Xiaohu, founder of Yunxuan Pharmaceutical, said: "As a fellow classmate from Peking University's Chemistry Department, I’m intimately familiar with Shengshitaike’s entrepreneurial team. What I admire most about Ding Juping and Yu Qiang is their exceptional ability to execute and manage the project effectively. I have no doubt they’ll nurture the compound I designed and synthesized—treat it like their own child—and ultimately develop it into a truly effective medicine."

Dr. Yu Qiang, CEO of Shengshi Taikang, expressed his heartfelt gratitude for the trust shown by his longtime classmate, stating: "Through head-to-head preclinical experiments, we’ve identified that Professor Zhang’s compound demonstrates best-in-class or first-in-class potential across multiple therapeutic areas—aligning perfectly with Shengshi Taikang’s R&D philosophy. After successfully strengthening our product pipeline in diabetes, we’re now beginning to see promising results in our initiatives targeting oncology and rare diseases. With the introduction of this groundbreaking candidate, it truly feels like the perfect move has been made, bringing the entire strategy to life."

According to the agreement, Shengshi Taikang will provide Yunxuan Pharmaceutical with phased returns in the form of advance payments, milestone-based R&D payments, and sales royalties.

Prev：

Shengshi Taikang's Yu Qiang: The innovative drug industry is a "Long March"—if you give up halfway, you lose.

Next：

Shengshi Taikang: The first domestically developed, original DPP-4 inhibitor, Sitagliptin, advances from "Phase 2 to Phase 3" without delay.

中企跨境-全域组件 制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地